ARGX vs. SYK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ARGX and SYK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
SYK’s market capitalization of 151.06 billion USD is significantly greater than ARGX’s 33.18 billion USD, highlighting its more substantial market valuation.
SYK carries a higher beta at 0.93, indicating it’s more sensitive to market moves, while ARGX (beta: 0.04) exhibits greater stability.
ARGX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, SYK is a standard domestic listing.
| Symbol | ARGX | SYK |
|---|---|---|
| Company Name | argenx SE | Stryker Corporation |
| Country | NL | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Devices |
| CEO | Timothy Van Hauwermeiren EMBA, | Kevin A. Lobo |
| Price | 543.48 USD | 395.28 USD |
| Market Cap | 33.18 billion USD | 151.06 billion USD |
| Beta | 0.04 | 0.93 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 18, 2017 | March 17, 1980 |
| ADR | Yes | No |
Historical Performance
This chart compares the performance of ARGX and SYK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ARGX
16.83%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
In the upper quartile for the Biotechnology industry, ARGX’s Return on Equity of 16.83% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
SYK
10.73%
Medical - Devices Industry
- Max
- 49.04%
- Q3
- 9.53%
- Median
- -7.46%
- Q1
- -32.83%
- Min
- -82.64%
In the upper quartile for the Medical - Devices industry, SYK’s Return on Equity of 10.73% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
ARGX
-118.38%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ARGX has a negative Return on Invested Capital of -118.38%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
SYK
5.99%
Medical - Devices Industry
- Max
- 21.88%
- Q3
- 6.63%
- Median
- -1.11%
- Q1
- -21.08%
- Min
- -51.95%
SYK’s Return on Invested Capital of 5.99% is in line with the norm for the Medical - Devices industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
ARGX
37.53%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
A Net Profit Margin of 37.53% places ARGX in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
SYK
12.31%
Medical - Devices Industry
- Max
- 44.80%
- Q3
- 9.77%
- Median
- -5.53%
- Q1
- -29.37%
- Min
- -87.68%
A Net Profit Margin of 12.31% places SYK in the upper quartile for the Medical - Devices industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ARGX
-1.24%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ARGX has a negative Operating Profit Margin of -1.24%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
SYK
15.77%
Medical - Devices Industry
- Max
- 30.13%
- Q3
- 13.12%
- Median
- 3.47%
- Q1
- -24.42%
- Min
- -80.56%
An Operating Profit Margin of 15.77% places SYK in the upper quartile for the Medical - Devices industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ARGX | SYK |
|---|---|---|
| Return on Equity (TTM) | 16.83% | 10.73% |
| Return on Assets (TTM) | 13.45% | 6.21% |
| Return on Invested Capital (TTM) | -118.38% | 5.99% |
| Net Profit Margin (TTM) | 37.53% | 12.31% |
| Operating Profit Margin (TTM) | -1.24% | 15.77% |
| Gross Profit Margin (TTM) | 46.33% | 63.57% |
Financial Strength
Current Ratio
ARGX
7.29
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ARGX’s Current Ratio of 7.29 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
SYK
1.64
Medical - Devices Industry
- Max
- 12.68
- Q3
- 6.30
- Median
- 4.05
- Q1
- 1.85
- Min
- 0.01
SYK’s Current Ratio of 1.64 falls into the lower quartile for the Medical - Devices industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
ARGX
0.01
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
Falling into the lower quartile for the Biotechnology industry, ARGX’s Debt-to-Equity Ratio of 0.01 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
SYK
0.31
Medical - Devices Industry
- Max
- 2.34
- Q3
- 1.09
- Median
- 0.37
- Q1
- 0.08
- Min
- 0.00
SYK’s Debt-to-Equity Ratio of 0.31 is typical for the Medical - Devices industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
ARGX
-20.85
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ARGX has a negative Interest Coverage Ratio of -20.85. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
SYK
--
Medical - Devices Industry
- Max
- 18.18
- Q3
- 7.53
- Median
- 0.85
- Q1
- -9.80
- Min
- -33.94
Interest Coverage Ratio data for SYK is currently unavailable.
Financial Strength at a Glance
| Symbol | ARGX | SYK |
|---|---|---|
| Current Ratio (TTM) | 7.29 | 1.64 |
| Quick Ratio (TTM) | 6.68 | 1.00 |
| Debt-to-Equity Ratio (TTM) | 0.01 | 0.31 |
| Debt-to-Asset Ratio (TTM) | 0.01 | 0.31 |
| Net Debt-to-EBITDA Ratio (TTM) | -189.75 | 2.27 |
| Interest Coverage Ratio (TTM) | -20.85 | -- |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ARGX and SYK. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
SYK
0.84%
Medical - Devices Industry
- Max
- 3.57%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.84%, SYK offers a more attractive income stream than most of its peers in the Medical - Devices industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
SYK
43.20%
Medical - Devices Industry
- Max
- 102.12%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SYK’s Dividend Payout Ratio of 43.20% is in the upper quartile for the Medical - Devices industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | ARGX | SYK |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.84% |
| Dividend Payout Ratio (TTM) | 0.00% | 43.20% |
Valuation
Price-to-Earnings Ratio
ARGX
48.48
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ARGX’s P/E Ratio of 48.48 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
SYK
52.77
Medical - Devices Industry
- Max
- 90.56
- Q3
- 56.92
- Median
- 43.19
- Q1
- 21.79
- Min
- 5.55
SYK’s P/E Ratio of 52.77 is within the middle range for the Medical - Devices industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ARGX
1.27
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
A Forward PEG Ratio of 1.27 places ARGX in the upper quartile for the Biotechnology industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
SYK
4.51
Medical - Devices Industry
- Max
- 6.56
- Q3
- 3.52
- Median
- 2.22
- Q1
- 0.55
- Min
- 0.03
A Forward PEG Ratio of 4.51 places SYK in the upper quartile for the Medical - Devices industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
Price-to-Sales Ratio
ARGX
15.66
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ARGX’s P/S Ratio of 15.66 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
SYK
6.51
Medical - Devices Industry
- Max
- 15.74
- Q3
- 8.12
- Median
- 3.40
- Q1
- 2.37
- Min
- 0.42
SYK’s P/S Ratio of 6.51 aligns with the market consensus for the Medical - Devices industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
ARGX
7.35
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
SYK
3.28
Medical - Devices Industry
- Max
- 16.65
- Q3
- 8.03
- Median
- 3.73
- Q1
- 1.92
- Min
- 0.65
SYK’s P/B Ratio of 3.28 is within the conventional range for the Medical - Devices industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | ARGX | SYK |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 48.48 | 52.77 |
| Forward PEG Ratio (TTM) | 1.27 | 4.51 |
| Price-to-Sales Ratio (P/S, TTM) | 15.66 | 6.51 |
| Price-to-Book Ratio (P/B, TTM) | 7.35 | 3.28 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -432.72 | 42.23 |
| EV-to-EBITDA (TTM) | 4329.99 | 30.66 |
| EV-to-Sales (TTM) | 15.00 | 7.03 |